Biogen (BIIB) and Eisai's Leqembi medicine has been approved to treat mild cognitive impairment in early stages of Alzheimer's disease, the European Commission said Tuesday.
The medicine is for use in patients who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain, the Commission said.
The approval makes Leqembi the first such medicine to be authorized in the EU, it added.
Biogen and Eisai did not immediately respond to MT Newswires' requests for comment.
Price: 117.13, Change: -2.13, Percent Change: -1.79
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.